{"rows":[{"id":5990,"title":"Psilocybin-Assisted Therapy for Existential Distress in Serious and Life-Limiting Illness: Emerging Trial Evidence, Barriers to Access, and the Case for Individualized Eligibility","authors":"Janis Ancans","journal":"PsyArXiv","publication_date":"2026-10-11","publication_year":2026,"doi":"10.31234/osf.io/jktdh_v1","pubmed_id":null,"openalex_id":null,"source_url":"https://osf.io/preprints/psyarxiv/jktdh_v1","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,End-of-Life Distress,Mechanism of Action,Review Article,Observational Study,Cancer Patients,Treatment-Resistant Depression","study_type":"Clinical Trial","source_name":"PsyArXiv","publication_status":"preprint","date_added":"2026-10-12 07:00:12","last_checked":"2026-10-16 01:30:29","bibtex":null,"source_record_id":"DOI:10.31234/osf.io/jktdh_v1","abstract_available":true,"abstract_source":"PsyArXiv","abstract_source_url":"https://osf.io/preprints/psyarxiv/jktdh_v1","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PsyArXiv","source_record_id":"DOI:10.31234/osf.io/jktdh_v1","source_url":"https://osf.io/preprints/psyarxiv/jktdh_v1","doi":"10.31234/osf.io/jktdh_v1","pmid":"","publication_date":"2026-10-11","importer_version":"2.1.3","text_redistributed":false}},{"id":3570,"title":"The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.","authors":"University Medical Center Groningen","journal":"ClinicalTrials.gov","publication_date":"2026-05-08","publication_year":2026,"doi":null,"pubmed_id":null,"openalex_id":null,"source_url":"https://clinicaltrials.gov/study/NCT06782724","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,End-of-Life Distress,Chronic Pain,Brain Imaging,Biomarkers,Spirituality,Clinical Trial,Safety,Adverse Events","study_type":"Clinical Trial","source_name":"ClinicalTrials.gov","publication_status":"clinical trial","date_added":"2026-07-01 11:04:28","last_checked":"2026-08-09 10:12:44","bibtex":null,"source_record_id":"https://clinicaltrials.gov/study/NCT06782724","abstract_available":true,"abstract_source":"ClinicalTrials.gov","abstract_source_url":"https://clinicaltrials.gov/study/NCT06782724","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"ClinicalTrials.gov","source_record_id":"https://clinicaltrials.gov/study/NCT06782724","source_url":"https://clinicaltrials.gov/study/NCT06782724","doi":"","pmid":"","publication_date":"2026-05-08","importer_version":"2.1.3","text_redistributed":false}}],"total":2,"page":1,"per_page":20,"pages":1,"resource":"papers","filters":{"q":"PsyPal","author":null,"substances":["psilocybin","psilocin"],"topic":null,"study_type":null,"cited_doi":null,"sources":[],"publication_statuses":[],"year":null,"journal":null,"from":null,"to":null,"added_from":null,"added_to":null,"sort":"newly_added","page":1,"per_page":"20"}}